Amgen Stock Price, News & Analysis (NASDAQ:AMGN)

$182.45 +0.02 (+0.01 %)
(As of 02/23/2018 08:48 AM ET)
Previous Close$182.43
Today's Range$182.01 - $185.16
52-Week Range$152.16 - $201.23
Volume3.87 million shs
Average Volume4.02 million shs
Market Capitalization$131.45 billion
P/E Ratio70.99
Dividend Yield2.89%
Beta1.42

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Debt-to-Equity Ratio1.35%
Current Ratio5.49%
Quick Ratio5.17%

Price-To-Earnings

Trailing P/E Ratio70.9922178988327
Forward P/E Ratio13.81
P/E Growth2.18

Sales & Book Value

Annual Sales$22.85 billion
Price / Sales5.75
Cash Flow$15.44 per share
Price / Cash11.82
Book Value$35.03 per share
Price / Book5.21

Profitability

Trailing EPS$2.57
Net Income$1.98 billion
Net Margins8.66%
Return on Equity30.87%
Return on Assets11.64%

Miscellaneous

Employees20,800
Outstanding Shares720,560,000

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 12th. Investors of record on Thursday, February 15th will be paid a dividend of $1.32 per share on Thursday, March 8th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $1.15. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its board has initiated a stock buyback plan on Friday, February 2nd 2018, which permits the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Thursday, February, 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts' consensus estimates of $3.03 by $0.14. The medical research company had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. Amgen's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $2.89 EPS. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $12.60-13.70 for the period, compared to the Thomson Reuters consensus estimate of $12.71. The company issued revenue guidance of $21.8-22.8 billion, compared to the consensus revenue estimate of $22.86 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2018?

22 brokerages have issued 12-month price objectives for Amgen's shares. Their predictions range from $161.00 to $220.00. On average, they expect Amgen's share price to reach $192.45 in the next twelve months. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)
  • 2. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)
  • 3. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)
  • 4. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)
  • 5. According to Zacks Investment Research, "Amgen beat expectations for both earnings and sales in Q3 and raised its earnings guidance for 2017. However sales declined year over year. Meanwhile sales of key drug Repatha disappointed in the quarter. Amgen’s newer drugs – Prolia, Xgeva, Vectibix and Sensipar – are performing well. Amgen is also progressing with its pipeline including biosimilar drugs. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature drugs. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta and Epogen could start facing the same next year. Also the softness in Enbrel sales due to stiff competitive pressure is a key cause for concern. Meanwhile, uptake of Repatha has been slow." (10/30/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • David W. Meline, Executive Vice President, Chief Financial Officer (Age 60)
  • Sean E. Harper, Executive Vice President - Research and Development (Age 54)
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations (Age 62)
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives (Age 60)
  • Esteban Santos, Executive Vice President, Operations (Age 49)
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer (Age 55)
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary (Age 56)
  • Lori A. Johnston, Senior Vice President (Age 52)
  • David A. Piacquad, Senior Vice President - Business Development (Age 60)

Who owns Amgen stock?

Amgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.85%), Geode Capital Management LLC (1.12%), Bank of New York Mellon Corp (1.11%), Clearbridge Investments LLC (1.03%), Franklin Resources Inc. (0.96%) and Renaissance Technologies LLC (0.63%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Credit Agricole S A, CI Global Investments Inc., Clearbridge Investments LLC, BlackRock Inc., Metropolitan Life Insurance Co. NY, Flossbach Von Storch AG and PGGM Investments. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Aristotle Capital Management LLC, Renaissance Technologies LLC, Millennium Management LLC, American Century Companies Inc., State of Tennessee Treasury Department, ADAMCAPITAL Gestao de Recursos Ltda. and APG Asset Management N.V.. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $182.45.

How big of a company is Amgen?

Amgen has a market capitalization of $131.45 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $2.57 on an earnings per share basis. Amgen employs 20,800 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (AMGN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,037 (Vote Outperform)
Underperform Votes:  649 (Vote Underperform)
Total Votes:  1,686
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amgen (NASDAQ:AMGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.452.482.502.57
Ratings Breakdown: 0 Sell Rating(s)
12 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $192.45$191.84$190.67$186.72
Price Target Upside: 10.95% upside0.08% downside8.82% upside11.62% upside

Amgen (NASDAQ:AMGN) Consensus Price Target History

Price Target History for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018MizuhoBoost Price TargetBuy -> Buy$192.00 -> $200.00LowView Rating Details
2/5/2018Atlantic SecuritiesDowngradeOverweight -> Neutral$187.01HighView Rating Details
2/4/2018JPMorgan Chase & Co.Reiterated RatingHold$191.00HighView Rating Details
2/2/2018Leerink SwannReiterated RatingMarket PerformHighView Rating Details
2/2/2018CowenReiterated RatingBuy$204.00LowView Rating Details
2/2/2018Credit Suisse GroupBoost Price TargetNeutral -> Neutral$191.00 -> $194.00LowView Rating Details
2/2/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$192.00 -> $202.00MediumView Rating Details
2/2/2018Morgan StanleyLower Price TargetOverweight -> Overweight$204.00 -> $196.00MediumView Rating Details
2/2/2018Piper Jaffray CompaniesLower Price TargetOverweight -> Overweight$194.00 -> $190.00MediumView Rating Details
1/30/2018OppenheimerReiterated RatingBuy$205.00 -> $205.00LowView Rating Details
1/24/2018Royal Bank of CanadaReiterated RatingHold$189.00LowView Rating Details
1/23/2018ArgusUpgradeHold -> Buy$192.33 -> $220.00LowView Rating Details
12/18/2017CitigroupDowngradeNeutralLowView Rating Details
12/15/2017Goldman Sachs GroupDowngradeConviction-Buy -> BuyHighView Rating Details
11/30/2017CannReiterated RatingBuy$205.00HighView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$180.00 -> $190.00N/AView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy$210.00N/AView Rating Details
9/25/2017Jefferies GroupReiterated RatingBuy$200.00LowView Rating Details
7/26/2017Deutsche BankReiterated RatingHold$172.00 -> $174.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Amgen (NASDAQ:AMGN) Earnings History and Estimates Chart

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018$3.18N/AView Earnings Details
2/1/2018Q4 2017$3.03$2.89$5.84 billion$5.80 billionViewListenView Earnings Details
10/25/2017Q3 2017$3.11$3.27$5.75 billion$5.77 billionViewN/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
4/24/2012Q1 2012$1.43$1.59ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
10/25/2010Q3 2010$1.26$1.36ViewN/AView Earnings Details
7/29/2010Q2 2010$1.28$1.34ViewN/AView Earnings Details
4/21/2010Q1 2010$1.23$1.28ViewN/AView Earnings Details
1/25/2010Q4 2009$1.11$1.05ViewN/AView Earnings Details
10/21/2009Q3 2009$1.25$1.49ViewN/AView Earnings Details
7/27/2009Q2 2009$1.15$1.27ViewN/AView Earnings Details
4/23/2009Q1 2009$1.13$1.08ViewN/AView Earnings Details
1/26/2009Q4 2008$1.04$1.04ViewN/AView Earnings Details
10/22/2008Q3 2008$1.06$1.21ViewN/AView Earnings Details
7/28/2008Q2 2008$0.98$1.13ViewN/AView Earnings Details
4/24/2008Q1 2008$1.02$1.10ViewN/AView Earnings Details
1/24/2008Q4 2007$0.92$0.97ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Amgen (NASDAQ:AMGN) Earnings Estimates

2018 EPS Consensus Estimate: $13.05
2019 EPS Consensus Estimate: $13.88
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$3.04$3.27$3.16
Q2 20183$3.08$3.55$3.29
Q3 20183$3.16$3.47$3.35
Q4 20183$3.13$3.34$3.25
Q1 20191$3.42$3.42$3.42
Q2 20191$3.52$3.52$3.52
Q3 20191$3.52$3.52$3.52
Q4 20191$3.42$3.42$3.42
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Amgen (NASDAQ:AMGN) Dividend Information

Next Dividend:3/8/2018
Annual Dividend:$5.28
Dividend Yield:2.89%
Dividend Growth:23.50% (3 Year Average)
Payout Ratio:205.45% (Trailing 12 Months of Earnings)
39.97% (Based on This Year's Estimates)
38.48% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/12/2017quarterly$1.322.98%2/14/20182/15/20183/8/2018
10/24/2017quarterly$1.152.59%11/16/201711/17/201712/8/2017
7/28/2017quarterly$1.152.64%8/15/20178/17/20179/8/2017
3/7/2017quarterly$1.152.59%5/15/20175/17/20176/8/2017
12/20/2016quarterly$1.153.15%2/13/20172/15/20173/8/2017
10/14/2016quarterly$1.002.46%11/14/201611/16/201612/8/2016
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Amgen (NASDAQ AMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.03%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018Sean E. HarperEVPSell1,525$174.18$265,624.50View SEC Filing  
1/16/2018Sean E. HarperEVPSell1,525$185.62$283,070.50View SEC Filing  
12/12/2017Sean E HarperEVPSell1,525$176.83$269,665.7556,106View SEC Filing  
11/13/2017Sean E HarperEVPSell1,525$171.58$261,659.5057,631View SEC Filing  
11/8/2017Carbonnel Francois DeDirectorSell4,000$173.61$694,440.00View SEC Filing  
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.8024,214View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.0023,097View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.5232,350View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.2542,248View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.0015,150View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.303,582View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.9018,589View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.2541,041View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.0018,343View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.1226,879View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
At $182.68, Amgen (AMGN) a Sell - Investorplace.comAt $182.68, Amgen (AMGN) a Sell - Investorplace.com
investorplace.com - February 23 at 8:12 AM
At $182.68, Amgen (AMGN) a SellAt $182.68, Amgen (AMGN) a Sell
investorplace.com - February 22 at 9:48 AM
Is Amgen Inc. a Buy? -- The Motley Fool - Motley FoolIs Amgen Inc. a Buy? -- The Motley Fool - Motley Fool
www.fool.com - February 22 at 8:00 AM
Is Amgen Inc. a Buy?Is Amgen Inc. a Buy?
finance.yahoo.com - February 21 at 8:37 AM
[$$] US companies might be liquidating their offshore bond hoards[$$] US companies might be liquidating their offshore bond hoards
finance.yahoo.com - February 20 at 5:34 PM
This week, Amgen (AMGN) a Sell | InvestorPlace - Investorplace.comThis week, Amgen (AMGN) a Sell | InvestorPlace - Investorplace.com
investorplace.com - February 17 at 8:01 AM
 Brokerages Anticipate Amgen, Inc. (AMGN) to Announce $3.18 Earnings Per Share Brokerages Anticipate Amgen, Inc. (AMGN) to Announce $3.18 Earnings Per Share
www.americanbankingnews.com - February 17 at 1:16 AM
This week, Amgen (AMGN) a SellThis week, Amgen (AMGN) a Sell
investorplace.com - February 16 at 11:33 AM
Sean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) StockSean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) Stock
www.americanbankingnews.com - February 15 at 9:44 PM
VYM, GE, MCD, AMGN: Large Inflows Detected at ETFVYM, GE, MCD, AMGN: Large Inflows Detected at ETF
www.nasdaq.com - February 15 at 5:34 PM
Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)
finance.yahoo.com - February 15 at 7:33 AM
Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17
finance.yahoo.com - February 14 at 7:37 AM
Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 14, 2018 - NasdaqAmgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 14, 2018 - Nasdaq
www.nasdaq.com - February 13 at 3:30 PM
Trade of the Day: Amgen, Inc. Remains a Promising Biotechnology PlayTrade of the Day: Amgen, Inc. Remains a Promising Biotechnology Play
investorplace.com - February 13 at 7:48 AM
Ex-Dividend Reminder: Amgen, Primerica and Monmouth Real ... - NasdaqEx-Dividend Reminder: Amgen, Primerica and Monmouth Real ... - Nasdaq
www.nasdaq.com - February 13 at 7:37 AM
Trade of the Day: Amgen, Inc. Remains a Promising Biotechnology Play - Investorplace.comTrade of the Day: Amgen, Inc. Remains a Promising Biotechnology Play - Investorplace.com
investorplace.com - February 13 at 7:37 AM
Better Buy: Amgen Inc. vs. Celgene - Motley FoolBetter Buy: Amgen Inc. vs. Celgene - Motley Fool
www.fool.com - February 13 at 7:37 AM
Amgen As A Source Of Funds - Seeking AlphaAmgen As A Source Of Funds - Seeking Alpha
seekingalpha.com - February 12 at 3:31 PM
What Will Drive Amgen’s Dividends?What Will Drive Amgen’s Dividends?
finance.yahoo.com - February 12 at 3:31 PM
Amgen (AMGN) Price Target Raised to $200.00Amgen (AMGN) Price Target Raised to $200.00
www.americanbankingnews.com - February 12 at 11:52 AM
First look: Inside Amgen’s “next-generation” workspace in TampaFirst look: Inside Amgen’s “next-generation” workspace in Tampa
finance.yahoo.com - February 12 at 7:30 AM
3 ETFs to Watch on Biotech Earnings - Yahoo Finance3 ETFs to Watch on Biotech Earnings - Yahoo Finance
finance.yahoo.com - February 11 at 7:43 AM
Forget Amgen -- Cara Therapeutics, Inc. Is a Better Growth StockForget Amgen -- Cara Therapeutics, Inc. Is a Better Growth Stock
www.fool.com - February 9 at 6:55 AM
Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet OncologyResults From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
www.prnewswire.com - February 8 at 7:49 PM
Amgen Breaks Below 200-Day Moving Average - Notable for AMGN - NasdaqAmgen Breaks Below 200-Day Moving Average - Notable for AMGN - Nasdaq
www.nasdaq.com - February 8 at 7:21 AM
Democrats slam Republican tax cut for $97 billion wave in corporate share buybacksDemocrats slam Republican tax cut for $97 billion wave in corporate share buybacks
finance.yahoo.com - February 8 at 7:21 AM
Amgen, Inc. (AMGN) Receives Average Recommendation of "Hold" from AnalystsAmgen, Inc. (AMGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 7 at 1:30 AM
Amgen (AMGN) Cut to Neutral at Atlantic SecuritiesAmgen (AMGN) Cut to Neutral at Atlantic Securities
www.americanbankingnews.com - February 5 at 8:42 PM
Cramer vs. Chaikin: Amgen -- Be Careful of This StockCramer vs. Chaikin: Amgen -- Be Careful of This Stock
finance.yahoo.com - February 5 at 3:28 PM
Amgen, Inc. Forecasted to Post FY2022 Earnings of $11.45 Per Share (AMGN)Amgen, Inc. Forecasted to Post FY2022 Earnings of $11.45 Per Share (AMGN)
www.americanbankingnews.com - February 5 at 9:32 AM
Amgen, Inc. (AMGN) to Post Q4 2018 Earnings of $3.34 Per Share, Leerink Swann ForecastsAmgen, Inc. (AMGN) to Post Q4 2018 Earnings of $3.34 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - February 5 at 8:00 AM
Amgen, Inc. (AMGN) to Post Q3 2018 Earnings of $3.41 Per Share, William Blair ForecastsAmgen, Inc. (AMGN) to Post Q3 2018 Earnings of $3.41 Per Share, William Blair Forecasts
www.americanbankingnews.com - February 5 at 4:56 AM
Amgen, Inc. (AMGN) Expected to Post Q1 2018 Earnings of $3.16 Per ShareAmgen, Inc. (AMGN) Expected to Post Q1 2018 Earnings of $3.16 Per Share
www.americanbankingnews.com - February 5 at 3:00 AM
Amgens (AMGN) "Hold" Rating Reiterated at JPMorgan Chase & Co.Amgen's (AMGN) "Hold" Rating Reiterated at JPMorgan Chase & Co.
www.americanbankingnews.com - February 4 at 8:02 AM
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft - NasdaqAmgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft - Nasdaq
www.nasdaq.com - February 4 at 7:25 AM
3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Edwards Lifesciences Corp (EW) and Motorola Solutions Inc (MSI) - Yahoo News3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Edwards Lifesciences Corp (EW) and Motorola Solutions Inc (MSI) - Yahoo News
finance.yahoo.com - February 4 at 7:25 AM
An Earnings Miss Ushers in an Era of Stagnation for Amgen, Inc. Stock - Investorplace.comAn Earnings Miss Ushers in an Era of Stagnation for Amgen, Inc. Stock - Investorplace.com
investorplace.com - February 4 at 7:25 AM
Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to LikeAmgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like
www.fool.com - February 3 at 12:29 PM
Dow Gets Crushed as Bad Week Gets WorseDow Gets Crushed as Bad Week Gets Worse
finance.yahoo.com - February 3 at 7:22 AM
Amgens (AMGN) Market Perform Rating Reiterated at Leerink SwannAmgen's (AMGN) Market Perform Rating Reiterated at Leerink Swann
www.americanbankingnews.com - February 3 at 6:54 AM
Amgen (AMGN) PT Lowered to $190.00Amgen (AMGN) PT Lowered to $190.00
www.americanbankingnews.com - February 2 at 11:32 PM
Amgen (AMGN) Price Target Cut to $196.00Amgen (AMGN) Price Target Cut to $196.00
www.americanbankingnews.com - February 2 at 11:32 PM
Amgen (AMGN) Price Target Increased to $202.00 by Analysts at BMO Capital MarketsAmgen (AMGN) Price Target Increased to $202.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - February 2 at 11:32 PM
Credit Suisse Group Boosts Amgen (AMGN) Price Target to $194.00Credit Suisse Group Boosts Amgen (AMGN) Price Target to $194.00
www.americanbankingnews.com - February 2 at 7:16 PM
Amgen (AMGN) Stock Rating Reaffirmed by CowenAmgen (AMGN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - February 2 at 4:06 PM
Amgen Inc. -- Moodys affirms Amgen at Baa1; outlook stableAmgen Inc. -- Moody's affirms Amgen at Baa1; outlook stable
finance.yahoo.com - February 2 at 3:32 PM
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View SoftAmgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft
finance.yahoo.com - February 2 at 3:32 PM
Investors love Amgen’s buybacks if not its growthInvestors love Amgen’s buybacks if not its growth
finance.yahoo.com - February 2 at 3:32 PM
Pharma Investors Suffer From Tax MyopiaPharma Investors Suffer From Tax Myopia
finance.yahoo.com - February 2 at 3:32 PM
Amgen Posts Fourth Quarter NumbersAmgen Posts Fourth Quarter Numbers
finance.yahoo.com - February 2 at 3:32 PM

SEC Filings

Amgen (NASDAQ:AMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amgen (NASDAQ:AMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amgen (NASDAQ AMGN) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.